Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK)
Colin H. MacKinnon, Kevin Lau, Jason D. Burch et al. · Bioorganic & Medicinal Chemistry Letters · 2013
Cited by 13 works. doi:10.1016/j.bmcl.2013.09.069
Authors
- Colin H. MacKinnon
- Jason D. Burch
- Yuan Chen
- Jonathon A. Dines
- Xiao Ding
- Charles W. Eigenbrot
- Alexander Heifetz
- Allan Jaochico
- Joachim Kraemer
- Susan Krüger
- Thomas M. Krülle
- Marya B. Liimatta
- Rosemary Maghames
- Christian Montalbetti
- Daniel F. Ortwine
- Yolanda Pérez-Fuertes
- Steven Shia
References
- Requirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity
- Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry
- Attenuation of Immunological Symptoms of Allergic Asthma in Mice Lacking the Tyrosine Kinase ITK
- Molecular design, synthesis, and structure–Activity relationships leading to the potent and selective p56lck inhibitor BMS-243117
- Selective Itk Inhibitors Block T-Cell Activation and Murine Lung Inflammation
- Hit-to-lead studies on benzimidazole inhibitors of ITK: Discovery of a novel class of kinase inhibitors
- Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay
- Crystal Structures of Interleukin-2 Tyrosine Kinase and Their Implications for the Design of Selective Inhibitors
- Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors
- 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk)